(CNN Español) – A volunteer participating in the Phase 3 clinical trial of the vaccine against the coronavirus of the Chinese laboratory Sinopharm in Peru has a neuralgia murmur by covid-19.
The Peruvian University Cayetano Heredia (UPCH) informs this March in a communiqué that a woman was treated to receive a placebo, not in the window. According to the institution, the participant receives treatment according to the principle of illness. Fue hospitalized with mechanical respiration and stevo “luchando por su vida” for more than one week, aggregate.
In its communication, the UPCH affirms that it is working closely with the security and vigilance team of the study and with regulatory entities with the aim of clarifying the sequence of advances that will take place on the death of the woman. Elaborarán informer to present the ethical bodies and regulators while continuing the habitual activities in the clinical study, aclararon.
In statements to Canal N, Germán Málaga, professor of medicine at the university and principal investigator of the clinical trial of the dosages, said that women should take diabetes and take medication for this disease. It has been stated that from the institution of exhortation in reiteration occasions to loswillarios to take the self-help mediators who are participating in a study in which, at present, the efficiency of the vacancy is known. Málaga informs that 12,000 people are receiving the 2 doses (vaccine and placebo) and there is now a lot of observation. The investigator calculates that “in a few weeks” the obstruction of the antigen may be obtained.
In December 2020, the Peruvian Ministry of Health temporarily suspended Sinopharm’s clinical trials, even though some of the authorities had announced that the situation had been clarified.
Until March, the sanitary card confirmed 1,107,239 cases of covid-19 in 40,107 deaths associated with the illness.